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Abstract 
Background: The aim of this analysis was to examine long‑term effects of changes in metabolic status on microvas‑
cular endothelial function and cardiovascular diseases (CVD) biomarkers among physically active middle‑aged men.
Methods: Metabolically healthy men (n = 101, mean age 59.7 years), free of symptoms and treatment, have been 
prospectively observed for their lifestyle and CVD risk factors (observation period 24.7 years). At the latest follow‑
up (2011/2012) a set of CVD biomarkers was measured using enzyme‑linked immunosorbent assay. Microvascular 
endothelial function was evaluated by means of the reactive hyperemia index (RHI) using Endo‑PAT2000 system. 
At follow‑up the participants were divided into metabolically healthy (0–1 metabolic parameters) and metaboli‑
cally unhealthy (≥2 metabolic parameters) groups. Metabolic syndrome was defined according to the NCEP ATP III 
definition.
Results: Traditional metabolic risk factors were significantly associated with hsCRP, ox‑LDL, Il‑6, leptin and adi‑
ponectin/leptin ratio. Reactive hyperemia index was negatively related to body mass (p < 0.01), waist circumference 
(p < 0.05), triglycerides (p < 0.01), TG/HDL ratio (p < 0.01), uric acid (p < 0.05), sICAM‑1 (p < 0.05) and Il‑6 (p < 0.05), 
and positively to HDL‑C (p < 0.01) and leisure‑time physical activity (p < 0.01). Men who maintained metabolically 
healthy status (n = 47) through the observation had significantly lower hsCRP and uric acid (p < 0.05), higher adi‑
ponectin/leptin ratio (p < 0.05), higher mean RHI and lower prevalence of endothelial dysfunction (p < 0.05) as com‑
pared to the metabolically unhealthy group (n = 54). Regular physical activity level was significantly higher among 
metabolically healthy individuals during the whole observation.
Conclusions: Even subtle changes in metabolic profile influence inflammatory biomarkers and microvascular 
endothelial function. Leptin, adiponectin/leptin ratio and hsCRP are significant predictors of metabolic profile. Inter‑
leukine‑6 and sICAM‑1 may be used as indicators of early endothelial dysfunction in asymptomatic men. High leisure‑
time physical activity level is an important contributor of metabolically healthy profile through middle adulthood.
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Background
Metabolic disorders, including visceral obesity, elevated 
blood pressure, lipids and glucose abnormalities, are 
known to be associated with cardiovascular diseases 
(CVD) [1]. Increased visceral fat and other metabolic dis-
turbances may impair nitric oxide bioactivity and cause 
endothelial dysfunction independently of traditional 
CVD risk factors [2]. It has been also shown that some 
metabolic components may enhance the release of sev-
eral hormones, inflammatory cytokines and molecules 
what may results in an impairment of endothelial func-
tion [3–6]. Identification of key biomarkers could be 
an important tool for early detection of metabolic risk 
before the appearance of its frank components.
Endothelial function measurement is thought to be a 
sensitive marker for a variety of cardiovascular (CVD) 
conditions and vascular health [7]. As endothelial dys-
function is the initial perturbation in development of 
atherosclerosis, identifying individuals with impaired 
endothelial function may substantially influence adverse 
CVD events [8, 9].
Physical activity (PA) is one of the fundamental factors 
modifying the metabolic profile and provides substantial 
CVD benefits [10–13]. It is postulated that protective 
effects of PA on vascular system may result from affect-
ing some biomarkers involved in development of ath-
erosclerosis and endothelial function, although precise 
mechanisms of this relationship remain unclear [14, 15].
Therefore, the aim of this analysis was to examine long-
term effects of changes in metabolic status on endothelial 
function and CVD biomarkers in the cohort of physically 
active men. In the Healthy Men Clinic of the Medical 
University of Lodz (Poland) we have a unique opportu-
nity to follow-up the population of apparently healthy 
physically active men for a period of above 25 years.
Methods
Study design and subjects
All the subjects were provided with written information 
about the purpose and methodology of the study. The 
protocol of the project has been approved by the Medical 
University of Lodz Ethics Committee.
Recruitment procedure and other methods has been 
described in our previous paper [12]. Briefly, the subjects 
of the study consisted of male volunteers who regularly 
attended the Healthy Men Clinic and the Department 
of Preventive Medicine, Medical University of Lodz 
(Poland) since 1985. Subjects were considered to be eli-
gible if before the examination they were asymptomatic, 
free from chronic diseases and treatment (including aspi-
rin, statins and anti-hypertensive agents) and any impor-
tant disability or dementia.
Previous structured follow-up examination was real-
ized in 2003–2005 within a scientific grant of the Min-
istry of Science and Higher Education. Data gathered 
in 2003–2005 were assessed for eligibility and 193 sub-
jects met preliminary inclusion criteria. Of the 193 sub-
jects personally invited by mail, 10 men did not respond, 
3 died in the years 2003–2012 (1 stroke, 1 cancer, 1 car 
accident), 23 were diagnosed with chronic diseases and 
24 was taking CVD drugs (information collected during 
a phone call). Of the 134 men (mean age 62.1 ± 3.6 years) 
who attended the Clinic in 2011/12, we disqualified 33 
subjects due to abnormalities found during physical 
examination, echocardiography or exercise test, and/or 
taking agents modifying CVD risk.
Therefore, the final cohort of the latest follow-up 
(2011–2012) consisted of 101 asymptomatic men aged 
50–77 years (mean age 59.7 ± 9.0 years; mean observa-
tion period: 24.7  ±  4.1  years). The subjects were white 
men, predominantly married, white collar workers with 
university or secondary educational level whose occu-
pational activity was low. In the years 1985–2005 all 
subjects participated in a similar panel of procedures 
including a detailed interviewer-administered question-
naire, anthropometric and biochemical measurements, 
resting electrocardiogram and the graded submaximal 
exercise test. The latest follow-up (2011/2012) included 
also an assessment of atherosclerosis indices and novel 
biomarkers.
Metabolic risk factors and physical activity measures
All the participants have completed a medical history 
questionnaire which included information on their health 
status, family history of CHD, smoking, nutrition habits, 
alcohol consumption and detailed information about lei-
sure-time physical activity (LTPA) since the initial visit.
Fasting blood samples were drawn from the antecu-
bital vein. Enzymatic methods were used to determine 
serum total cholesterol, glucose, triglycerides, uric acid 
concentrations (COBAS INTEGRA 400 Plus, Roche). 
High-density lipoproteins (HDL-C) were measured by 
the precipitation method. Concentration of low-density 
lipoproteins (LDL-C) was estimated using the Friedewald 
formula. Anthropometric data were collected by stand-
ard methods.
Metabolic disorders for males were defined according 
to the National Cholesterol Education Program Adult 
Treatment Panel III (NCEP ATP III) guidelines [16]. Met-
abolic syndrome was defined as the presence of 3 or more 
of the following parameters: waist circumference (WC) 
≥102  cm, systolic and/or diastolic blood pressure (BP) 
≥130/85 mmHg, triglycerides (TG) ≥1.7 mmol/l, HDL-C 
<1.0 mmol/l, fasting plasma glucose (FPG) ≥6.1 mmol/l. 
Page 3 of 10Kwaśniewska et al. Diabetol Metab Syndr  (2015) 7:81 
[16]. Individuals with zero or one metabolic disorder 
were categorized as metabolically healthy.
Leisure-time physical activity has been assessed by an 
interviewer-administered questionnaire. Exercise-related 
energy expenditure (EE) was assessed on the basis of the 
amount of hours earmarked for weekly recreational sport 
activities (kcal/week) according to the tables of Fox [17]. 
Historical LTPA was assessed according to Kriska [18] for 
the following periods of life: 12–34, 35–49, over 50 years 
old period, for the last 5 and 10 years and for the whole 
period from 12th year of life to the day of examination. 
All the measures of historical LTPA are expressed as 
hours per year for a given period.
In order to assess aerobic fitness the graded submaxi-
mal exercise test was carried out on a Monark type 818E 
(Stockholm, Sweden) bicycle ergometer with 30 W incre-
ments every 3  min to achieve at least 85  % of maximal 
age-predicted HR (220-age). The resultant linear regres-
sion equation was used to calculate the aerobic capacity 
index, i.e. physical working capacity at 85 % of the maxi-
mal heart rate (PWC85%HRmax) [19]. PWC85%HRmax 
was expressed as relative to body mass [PWC/kg 
(W kg−1)].
Cardiovascular biomarkers. Plasma concentration of 
high-sensitivity C-reactive protein (hsCRP), homocyst-
eine (Hcy), interleukine-6 (Il-6), oxidized low-density 
lipoproteins (ox-LDL), soluble intracellular adhesion 
molecule-1 (sICAM-1), soluble vascular cell adhesion 
molecule-1 (VCAM-1), leptin, resistin, adiponectin and 
irisin were measured using enzyme-linked immunosorb-
ent assay kit (Diaclone, France; Labor Diagnostika Nord, 
Germany; BioVendor, Czech Republic; Immundiagnostik 
AG, Germany; Axis-Shield Diagnostics Ltd., Scotland). 
Fasting serum was stored according to the manufactur-
er’s recommendations.
Microvascular endothelial function. Peripheral arte-
rial tonometry signals were obtained using the Endo-
PAT 2000 device (Itamar MedicalInc., Caesarea, Israel) 
in participants resting in the supine position in quiet, 
temperature-controlled environment after an overnight 
fast. Subjects were also instructed to refrain from smok-
ing and strenuous exercise at least 12 h before the exam-
ination. Briefly, a PAT finger probe was placed on each 
index finger. Pulsatile volume changes of the distal digit 
induced pressure alterations in the finger cuff, which 
were sensed by pressure transducer and transmitted to 
and recorded by the EndoPAT 2000 device. Blood pres-
sure (BP) and heart rate (HR) were measured by an auto-
mated BP monitor. Endothelial function was assessed 
via RH-PAT index. An RH protocol consists of a 5  min 
baseline measurement, after which a blood pressure cuff 
on the test arm was inflated to 60 mmHg above baseline 
systolic blood pressure or at least 200 mmHg for 5 min. 
Occlusion of pulsatile arterial flow was confirmed by the 
reduction of the PAT tracing to zero. After 5 min, the cuff 
was deflated, and the PAT tracing was recorded for a fur-
ther 6 min. The ratio of the PAT signal after cuff release 
compared with baseline was calculated through a com-
puter algorithm automatically normalizing for baseline 
signal and indexed to the contra lateral arm. The esti-
mated ratio reflects the RHI. RHI values <1.67 were con-
sidered abnormal [20].
Statistical analysis
Continuous variables are expressed as mean ± standard 
deviation (SD) or median (if not standard distribution). 
Wilcoxon signed-rank test was used to assess the differ-
ences between baseline and final characteristics of the 
study cohort. Categorical variables were compared by 
Chi square test or Chi square test with Yate’s correction. 
Spearman’s correlation was used to evaluate the associa-
tion between metabolic risk factors, RHI and biomarkers. 
The correlations were adjusted for WC, body mass, BP, 
lipids and glucose. Mann–Whitney test was used to com-
pare historical LTPA during different life periods. Loga-
rithmic transformation of skewed data did not change 
the direction or strength of the analyzed calculations. A 
p value <0.05 was considered statistically significant. All 
analyses were performed with STATISTICA Windows 
XP version 9.1.
Results
Table 1 presents 25-year changes in lifestyle and clinical 
characteristics of the studied group between the base-
line and final examination. While most of the parameters 
worsened, the number of regular smokers fell and HDL-C 
level increased substantially throughout the observation 
(p < 0.05). The studied population is thought as metaboli-
cally healthy at baseline as only two persons had more 
than one MetS components (borderline values of systolic 
blood pressure and triglycerides).
Among analyzed biomarkers, hsCRP, ox-LDL, Il-6, 
leptin and adiponectin/leptin ratio were significantly 
related with traditional metabolic risk factors (Table 2). 
Waist circumference was positively related with hsCRP 
(p  <  0.01), ox-LDL (p  <  0.05), leptin (p  <  0.05) and 
negatively with adiponectin/leptin ratio; HDL-C was 
negatively related with hsCRP (p < 0.01), Il-6 (p < 0.05) 
and positively with adiponectin/leptin ratio (p  <  0.05); 
TG level was positively related to leptin (p < 0.01) and 
negatively to adiponectin/leptin ratio (p  <  0.05); uric 
acid was positively related with hsCRP (p  <  0.05), lep-
tin (p  <  0.01) and negatively with adiponectin/leptin 
ratio (p  <  0.05). Significant negative correlations was 
found between RHI and sICAM-1 (p  <  0.05) and Il-6 
(p < 0.05).
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Table 3 shows relationships between metabolic param-
eters, LTPA characteristics and endothelial function in 
the whole group. Significant positive correlations were 
found between RHI, HDL-C (p < 0.01), current and his-
torical LTPA (p  <  0.01). Body mass, WC, TG, TG/HDL 
ratio, uric acid and number of metabolic risk factors were 
negatively related to RHI.
Approximately half of the studied cohort remained 
metabolically healthy at follow-up (Table  4). At base-
line no significant differences in traditional CVD risk 
factors were found between metabolically healthy and 
unhealthy groups. At follow-up metabolically unhealthy 
individuals had significantly higher percentage of body 
fat (p < 0.001), higher hsCRP and uric acid (p < 0.05) and 
lower adiponectin/leptin ratio (p  <  0.05). They had also 
significantly higher mean values of triglycerides (1.30 vs 
1.03 mmol/l; p < 0.01) and glucose (5.23 vs 4.75 mmol/l; 
p  <  0.01), and lower HDL-C (1.40 vs 1.77  mmol/l; 
p < 0.01) as compared to metabolically healthy subjects.
Regarding endothelial function, metabolically healthy 
individuals had higher mean RHI and lower number of 
decreased RHI (p < 0.05) (Table 4). Metabolically healthy 
individuals had significantly higher LTPA level and aero-
bic capacity at baseline and follow-up. Of 15 smokers at 
baseline, nine individuals followed the medical advice 
and gave up smoking during first 3 years of the observa-
tion. Only one person gave up smoking 5  years before 
the latest follow-up. No significant difference were found 
in terms of smoking history and alcohol consumption 
between the groups (Table 4).
Metabolic syndrome was found in 9 individuals at 
follow-up. Among metabolically unhealthy subjects 
(n = 51) no substantial differences in biomarkers profile 
Table 1 Baseline and  final characteristics of  the studied 
group (n = 101)
Data presented as mean ± SD unless otherwise stated; * p < 0.05; ** p < 0.01; 
*** p < 0.001
BMI body mass index, HDL-C high density lipoproteins, PWC physical working 
capacity
Baseline Follow-up
Age, years 35.3 ± 6.4 59.7 ± 9.0***
Waist circumference, cm 85.1 ± 6.9 93.4 ± 7.9*
BMI, kg/m2 24.3 ± 2.8 25.1 ± 3.2
Body fat,  % 16.1 ± 4.2 20.2 ± 5.8*
Waist circumference ≥102 cm 1 24**
Systolic blood pressure, mmHg 120.3 ± 12.9 128.4 ± 12.7*
Diastolic blood pressure, mmHg 78.1 ± 6.6 79.6 ± 7.7
Blood pressure ≥130/85 mmHg, n 19 42*
Triglycerides, mmol/l 1.27 ± 0.44 1.19 ± 0.44
TG ≥1.7 mmol/l, n 16 15
HDL‑C mmol/l 1.30 ± 0.28 1.57 ± 0.28*
HDL‑C <1.0 mmol/l 8 6
Fasting plasma glucose, mmol/l 4.52 ± 0.56 4.99 ± 0.46*
Fasting plasma glucose ≥6.1 mmol/l,  
n
1 12**
Uric acid, µmol/L 0.09 ± 0.01 0.10 ± 0.02
Metabolic syndrome, n 0 9**
TG/HDL ratio 0.98 ± 0.4 0.77 ± 0.3
Current smokers, n 17 5*
Alcohol consumption, units/week 4.71 ± 3.6 5.63 ± 4.3
Leisure‑time physical activity, hours/week
 Low/moderate intensity (≤6 METs) 2.9 ± 2.98 3.0 ± 2.66
 High/very high intensity (>6 METs) 4.8 ± 1.9 4.1 ± 1.1
Exercise‑related energy expenditure, 
kcal/week
3101.3 ± 2871.8 2735.3 ± 1872.5
PWC, W/kg 2.41 ± 0.56 1.97 ± 0.49*
Table 2 Correlation of  traditional metabolic risk factors and  reactive hyperemia index to  novel CVD biomarkers at  fol-
low-up
WC waist circumference, SBP systolic blood pressure, TG triglycerides, hsCRP high-sensitvity C-reactive protein, sICAM-1 soluble intracellular adhesion molecule-1, 
sVCAM-1 soluble vascular cell adhesion molecule-1, ox-LDL oxidized low-density lipoproteins
* p < 0.05; ** p < 0.01; *** p < 0.001
WC HDL-C SBP TG glucose Uric acid Reactive hyperemia index
hsCRP, mg/L 0.255** −0.272** 0.158 0.151 0.068 0.199* −0.158
Homocysteine, µmol/L −0.068 −0.038 0.183 0.049 −0.024 0.058 0.017
ox‑LDL, ng/mL 0.230* −0.156 0.171 0.151 0.173 0.106 0.018
sICAM‑1, ng/mL 0.111 0.045 0.041 0.053 −0.122 0.161 −0.228*
sVCAM‑1, ng/mL 0.095 −0.008 −0.035 −0.011 −0.127 0.039 −0.070
Interleukin‑6, pg/mL 0.059 −0.215* 0.157 0.166 0.043 0.075 −0.257*
Leptin, ng/mL 0.193* −0.171 0.107 0.282** 0.043 0.285** −0.010
Resistin, ng/mL −0.025 0.067 0.148 0.021 −0.087 0.027 −0.145
Adiponectin, µmol/L −0.051 −0.132 −0.148 0.051 −0.089 0.077 0.102
Adiponectin/leptin ratio −0.177* 0.193* −0.158 −0.209* −0.045 −0.222* 0.060
Irisin, µmol/L 0.005 −0.090 −0.124 −0.015 0.017 −0.042 −0.039
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and RHI were noted between those with and without 
MetS (data not shown in the tables).
Discussion
To our knowledge this is the first research on the relation-
ship between long-term changes of metabolic status, novel 
CVD biomarkers and microvascular endothelial function in 
the cohort of men tracked prospectively for about 25 years.
According to our results leptin, adiponectin/leptin ratio 
and hs-CRP are significant predictors of metabolic status. 
Most traditional risk factors, uric acid, Il-6 and sICAM-1 
correlate with endothelial function as measured by RHI. 
Particularly important finding of this analysis is that even 
subtle changes in metabolic profile in asymptomatic 
physically active individuals modify inflammatory mark-
ers and microvascular endothelial function. Maintaining 
metabolically healthy status through middle adulthood 
is associated with better endothelial function and more 
favorable biochemical profile. Among the analyzed 
Table 3 Correlation between  metabolic risk factors 
and reactive hyperemia index at final examination
Data presented as mean ± SD unless otherwise stated; * p < 0.05; ** p < 0.01; 
*** p < 0.001
HDL-C high density lipoproteins, LTPA leisure-time physical activity
Metabolic risk factors Reactive hyperemia index
Waist circumference, cm −0.18*
Body mass, kg −0.26**
Systolic blood pressure, mmHg −0.13





Uric acid, µmol/L −0.21*
Current LTPA, kcal/week 0.27**
Historical LTPA since 12th year of life,  
hours/year
0.29**
Table 4 Anthropometric, biochemical and endothelial indices according to metabolic status at follow up
Abbreviations as in the previous tables
* p < 0.05; ** p < 0.01; *** p < 0.001; # p = 0.0502
Metabolic status at follow-up
Metabolically healthy (0–1 factors) n = 47 Metabolically unhealthy (≥2 factors) n = 54
Age, years 61.0 ± 10.1 59.1 ± 8.4
Body fat,  % 17.1 ± 4.0 22.2 ± 4.7***
Waist circumference ≥102 cm, n 1 23***
BMI ≥30 kg/m2, n 0 8*
RHI 2.06 ± 0.48 1.91 ± 0.42*
RHI <1.67, n 5 15*
Uric acid, µmol/L 0.08 ± 0.01 0.10 ± 0.02*
hsCRP, mg/L 2.31 ± 1.15 2.73 ± 1.14*
Homocysteine, µmol/lL 13.25 ± 6.3 14.95 ± 4.7
ox‑LDL (median), ng/mL 99.85 ± 181.4 (29.1) 115.92 ± 226.7 (39.5)
sICAM‑1, ng/mL 486.60 ± 117 502.25 ± 143.53
sVCAM‑1, ng/mL 657.58 ± 250.0 749.05 ± 263.4
Interleukin‑6, pg/mL 2.67 ± 2.1 2.78 ± 2,7
Leptin, ng/mL 5.91 ± 4.5 7.75 ± 6.4#
Resistin, ng/mL 4.52 ± 1.8 4.99 ± 2.9
Adiponectin, µmol/L 8.15 ± 3.2 7.48 ± 2.5
Adiponectin/leptin ratio 1.41 ± 0.7 0.91 ± 0.4*
Irisin, µmol/L 0.49 ± 0.2 0.50 ± 0.1
EE at baseline, kcal/week 4558.7 ± 3233.0 2638.5 ± 2198.7***
EE at follow‑up, kcal/week 3230.8 ± 2150.0 2661.0 ± 2375.6*
VO2max, ml/kg/min 35.1 ± 8.9 30.1 ± 8.2*
PWC, W/kg 2.09 1.83*
Smoking at baseline, n 9 8
Smoking at follow‑up, n 3 2
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lifestyle-related factors, long-term physical activity level 
occurred the most important contributor of metabolic 
changes in the studied cohort.
Metabolic syndrome is a constellation of factors 
deeply involved in atherosclerosis. Even in asympto-
matic individuals, presence of larger WC, elevated TG, 
low HDL-C, prediabetes or prehypertension may accel-
erate development of atherosclerosis [21, 22]. Impaired 
endothelial function is among the earliest detectable dis-
turbance in the natural history of atherosclerosis [23]. Li 
et  al. showed that individuals with MetS have a higher 
degree of endothelial dysfunction compared with indi-
viduals with multiple CV risk factors [24]. These findings 
emphasize a unique position of metabolic disturbances 
in prediction of adverse CV events beyond the contri-
butions of traditional risk factors. It seems that factors 
which are not commonly included into popular risk algo-
rithms (as visceral adiposity, body weight, glucose pro-
file) provide substantial information on vascular health. 
Endothelial dysfunction was also found among asymp-
tomatic individuals with obesity and prediabetes. Gupta 
et al. demonstrated that obese men and women with pre-
disease conditions had resting endothelial dysfunction as 
compared to non-obese persons with normal glucose and 
blood pressure [25]. Also weight gain in healthy individu-
als may result in cardiovascular risk escalation, includ-
ing impaired endothelial function [26]. In our study we 
did not find substantial differences in endothelial func-
tion between individuals with and without MetS. It was 
expected due to a small number of men who developed 
MetS during the observation (n =  9). However, signifi-
cantly better RHI values (both mean and number of sub-
jects with RHI <1.67) were observed among those who 
maintained metabolically healthy profile. These findings 
suggest that even subtle changes in metabolic param-
eters among asymptomatic individuals may accelerate 
endothelial dysfunction.
Most, but not all, metabolic components occurred sig-
nificantly correlated with endothelial function which is 
in line with some previous studies in this field [27–30]. 
We have not found, however, independent correlation 
between FPG, blood pressure and endothelial function 
which is consistent with some other studies that incor-
porated reactive hyperemia index measurement [24, 29]. 
In contrast, Carnovale et  al. reported strong relation-
ship between all MetS components and RHI, but all the 
participants of this study (including post-menopausal 
women) had central obesity and differed substantially 
from our cohort [30].
Precise mechanism linking metabolic disorders with 
endothelial dysfunction are not clear. Apart from the 
traditionally measured parameters, insulin resistance is 
thought to exert specific role in vascular health. Insulin 
resistance may impair nitric oxide bioavailability and 
itself cause endothelial damage [31]. In the present analy-
sis, we have not measured insulin resistance. However, 
substantial abnormalities in insulin metabolism would be 
improbable due to a relatively high PA level of our cohort. 
Some previous studies and the latest report of Peterson 
et  al. indicate that moderate and vigorous PA is among 
the strongest predictors of insulin resistance in middle-
aged and older men [32].
Besides insulin resistance, several biochemical mark-
ers are involved in endothelial homeostasis, metabolic 
risk and atherosclerosis. Recent findings from basic sci-
ence highlight the fundamental role of inflammation in 
all stages of development of atherosclerosis. The strong-
est evidence is associated with hsCRP [33]. Several stud-
ies demonstrated independent association between 
elevated hsCRP levels and increased CVD risk as well 
as impairment of insulin signaling and reduced nitric 
oxide release from endothelial cells [33–36]. Elevation 
of hsCRP indicating a chronic low-grade inflammation 
predicts risk of atherosclerotic complications indepen-
dently of traditional CVD risk factors and myocardial 
damage [33]. Our results showed significant relationship 
of hsCRP with WC, HDL-C and uric acid. Importantly, 
metabolically healthy individuals had significantly lower 
levels of hsCRP as compared to those who developed at 
least two metabolic risk factors. This finding is of special 
importance as individuals with both increased inflamma-
tion and endothelial dysfunction represent particularly 
high CVD risk [3]. However, no significant correlation 
was found between hsCRP and RHI. Similar results were 
reported by Konttinen et  al. which might suggest that 
other biomarkers would be more sensitive in identifying 
the earliest stages of endothelial dysfunction [29].
Several studies have demonstrated that increased level 
of serum uric acid, even within the normal range, is asso-
ciated with CVD risk factors and future development of 
MetS [37, 38]. This is in line with our findings as uric acid 
occurred significantly higher in metabolically unhealthy 
individuals at follow up. We are unaware of any study 
assessing the relationship between uric acid and reactive 
hyperemia index in asymptomatic adults using a periph-
eral arterial tonometry device. We found that serum uric 
acid was significantly related to RHI which is consistent 
with some other studies measuring endothelial function 
with different methods [39]. This finding emphasize the 
position of this marker as an independent predictor of 
metabolic disorders and endothelial dysfunction.
However, it should be noted that inflammatory mark-
ers do not pinpoint the exact location of inflammation. 
C-reactive protein and some other biomarkers measure 
general levels of inflammation and elevated levels may 
be caused by infections and many chronic conditions. In 
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order to find the exact site of tissue inflammation more 
specific test may be performed. In the context of vascular 
and cardiometabolic health, adipose tissue seem particu-
larly important. There is a growing evidence that adipose 
tissue is an active organ able to release several mediators 
affecting metabolic and vascular health like Il-6, TNF-
alpha, adipokines [33, 40]. Excess adipose tissue is accom-
panied macrophage infiltration and cytokines released in 
this process spill into the circulation and probably result 
in systemic inflammation. Elevated CRP level seem to 
reflect a systemic response to localized inflammation in 
adipose tissue [41].
Among adipocyte-derived factors, the principal role 
in modifying metabolic profile has been established for 
leptin and adiponectin [42–45]. Leptin, an adipocyte-
derived hormone, is involved in angiogenesis, oxidative 
stress, sympathetic activation and prothrombotic pro-
cesses. Majority of studies have documented a significant 
relationship between higher leptin concentrations and an 
increased risk of obesity, hypertension, metabolic syn-
drome as well as markers of inflammation and thrombo-
philia [42–45]. Serum leptin has also been identified as 
an independent predictor of metabolic syndrome in men 
[46]. In contrast to leptin, adiponectin, an adipocyte-
derived collagen-like protein, has been generally reported 
as a protective factor with an anti-inflammatory and anti-
atherogenic properties [47].
Consistently to some previous findings, our results 
indicated that leptin was positively associated with waist 
circumference, TG and uric acid [43, 46]. Furthermore, 
we observed that adiponectin/leptin ratio was signifi-
cantly higher in metabolically healthy men. Significant 
correlation between adiponectin/leptin ratio and TG 
confirms the results obtained by Vega and Grundy [48].
Due to the rising interest in the role of irisin in preven-
tion of obesity and metabolic disorders, we included this 
novel myokine into the analyzes. Irisin has been shown 
to induce conversion of white adipocytes into brown-
like adipocytes [49]. To date, different researchers have 
reported conflicting results [49–51]. In our study we have 
not found any significant associations between irisin and 
analyzed parameters. Similarly, Huh et  al. have recently 
found that the exercise-induced change in irisin levels 
did not differ between healthy individuals and subjects 
with metabolic syndrome regardless of exercise type [50]. 
However, in another study, circulating irisin was nega-
tively correlated with BMI and waist circumference and 
positively with endothelial function [51]. These discrep-
ancies may result from substantial methodological differ-
ences between the studies. Our cohort was much older, 
with various metabolic disorders while the population of 
the study of Hou et al. (n = 41) consisted of nonhyper-
tensive, not smoking, nondiabetic obese and lean healthy 
controls. Moreover, endothelial function was measured 
by means of ultrasound scanner. Further studies with 
larger sample sizes and more severe metabolic disorders 
are needed to clarify the role of irisin in modifying meta-
bolic profile and endothelial function.
Reactive hyperemia index occurred inversely associated 
with sICAM-1 and Il-6 which is in line with the findings 
obtained by other authors investigating the association 
between inflammatory biomarkers and endothelial func-
tion [30, 52–54]. The initial stages of atherosclerosis 
associated with adhesion of circulating leukocytes to 
the endothelial cells are mediated by cellular adhesion 
molecules, including sICAM-1 [55]. Interleukine-6 is 
also thought as a key inflammatory cytokine that plays 
a central role in propagating the downstream inflamma-
tory response responsible for atherosclerosis [56]. Both 
markers reflect impaired microvascular function and 
could be, therefore, used as early markers of endothelial 
dysfunction.
It would be worthwhile to speculate why some of the 
participants developed metabolic disorders while others 
remained metabolically healthy. Among possible contrib-
utors we considered several factors, including smoking 
(especially smoking cessation), alcohol consumption, diet 
and physical activity level. Baseline and final character-
istics of metabolically healthy and unhealthy individuals 
revealed substantial differences only in terms of weekly 
exercise-related energy expenditure and aerobic capac-
ity. Therefore, it seems that long-term PA pattern was the 
most important contributor of metabolic changes in the 
studied cohort.
The obtained results support our previous findings 
that sufficient prevention of metabolic disorders may 
be achieved with regular high PA level substantially 
exceeding current recommendations [12]. Importantly, 
in the metabolically healthy group percent of body fat 
remained stable throughout the whole observation and 
only one person developed central obesity. The above 
effects together with better endothelial function may be 
associated with dose and intensity of exercises. Interest-
ing study of Hallmark et  al. revealed that high-intensity 
exercises acutely enhanced endothelial function, while 
moderate-intensity exercise was not significant in young 
lean subjects. The endothelial response of obese adults 
was blunted compared to lean adults [57]. Of note, vast 
majority of metabolically healthy subjects in our study 
was involved mainly in vigorous exercises.
A number of limitations of the present study should 
be acknowledged. The study is not representative for 
middle-aged men, because the participants were not ran-
domly selected from the general population. Well known 
limitation is related to self-reported questionnaires on PA 
which are prone to recall bias. Due to the cross-sectional 
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assessment of novel biomarkers and indices of endothe-
lial function only at follow-up examination we could not 
fully determine the direction of causality. Unfortunately 
we did not assess free fatty acids in our cohort. However, 
owing the significance of this factor in metabolic charac-
teristic of the MetS, we will include free fatty acids into 
the panel of measured markers during next follow-up.
Among various methods to measure endothelial func-
tion, we chose the system assessing microvascular 
endothelial function. The endoPAT system is a relatively 
simple, non-invasive, digital method of assessing micro-
vascular function by measuring postocclusive reactive 
hyperemia. Another recognized non-invasive method of 
measuring endothelial function is brachial artery flow-
mediated dilation (FMD) which is based on the meas-
urement of the brachial artery diameter before and after 
acute brachial artery occlusion [58]. However, FMD 
is technically challenging, relatively complex, and the 
results are difficult to compare between clinical laborato-
ries. Direct comparison of both methods is difficult as the 
brachial and digital measures of vascular function pro-
vide distinct information and therefore may reflect dif-
ferent conditions. Growing evidence show that RH-PAT 
may be complementary to FMD. Importantly, Sauder 
et al. have recently demonstrated that peripheral arterial 
tonometry can be used to assess endothelial dysfunction 
in adults with the metabolic syndrome as reliably as in 
healthy samples [59]. Finally, it should be noted that the 
experimental design of the study did not entail vascular 
smooth muscle function.
The distinct strength of the study is a long-term pro-
spective observation of CVD risk factors and health-
related behaviors in a unique cohort of men with 
comparable metabolic profile at baseline. We assessed a 
large set of biochemical markers in relation to traditional 
metabolic risk factors and reactive hyperemia. Longi-
tudinal observation of a homogenous group enables 
to eliminate the risk associated with such known con-
founders such as age, social class or lifestyle choices. We 
excluded individuals taking drugs modifying CVD risk, 
which could influence on endothelial function in order 
to reduce the confounding effect of anti-atherogenic 
treatment.
In summary, this prospective study in physically active 
asymptomatic men indicated that even subtle changes 
in metabolic profile may have an impact on traditional 
and novel CVD biomarkers as well as microvascular 
endothelial function. Maintaining metabolically healthy 
status through middle adulthood may protect against 
endothelial dysfunction. Leptin, adiponectin/leptin ratio 
and hsCRP are significant predictors of metabolic profile. 
Among analyzed biomarkers, Il-6 and sICAM-1 may be 
used as indicators of an early endothelial dysfunction. 
Long-term high PA level accompanied by high aerobic 
capacity are principal lifestyle-related contributors of 
metabolically healthy profile.
Authors’ contributions
Conceived and designed the experiments: MK, WD. Performed the experi‑
ments: MK, JK, MO. Analyzed the data: MK, EDZ, MO, WD. Contributed 
reagents/materials/analysis tools: WD, MK, AJ, TK, ER. Wrote the paper: MK, WD, 
JK, JL. All authors read and approved the final manuscript.
Author details
1 Department of Preventive Medicine, Medical University of Lodz, Zeligowsk‑
iego 7/9, 90‑752 Lodz, Poland. 2 Department of Epidemiology and Biostatistics, 
Medical University of Lodz, Zeligowskiego 7/9, 90‑752 Lodz, Poland. 3 Depart‑
ment of Geriatrics, Medical University of Lodz, Zeromskiego 113, Lodz, Poland. 
4 Department of Sports Medicine, Medical University of Lodz, Pomorska 251, 
92‑213 Lodz, Poland. 5 Central Clinical Hospital, Medical University of Lodz, 
Pomorska 251, 92‑213 Lodz, Poland. 6 Department of Epidemiology, Cardio‑
vascular Disease Prevention and Health Promotion, Institute of Cardiology, 
Niemodlinska 33, 04‑635 Warsaw, Poland. 
Acknowledgements
The study was supported by the scientific Grant NN 404 258940 from the 
National Science Centre (Poland). The authors were partially supported by the 
Healthy Ageing Research Centre Project (REGPOT‑2012‑2013‑1, 7FP).
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 6 July 2015   Accepted: 7 September 2015
References
 1. Grundy SM. Pre‑diabetes, metabolic syndrome, and cardiovascular risk. J 
Am Coll Cardiol. 2012;59:635–43. doi:10.1016/j.jacc.2011.08.080.
 2. Czernichow S, Greenfield Galan P, et al. Macrovascular and microvascular 
dysfunction in the metabolic syndrome. Hypertens Res. 2010;33:293–7.
 3. Vanhoutte PM, Shimokawa H, Tang H, Feletou M. Endothelial dysfunction 
and vascular disease. Acta Physiol (Oxf ). 2009;196:193–222.
 4. Nishida M, Moriyama T, Ishii K, Takashima S, Yoshizaki K, Sugita Y, 
Yamauchi‑Takihara K. Effects of IL‑6, adiponectin, CRP and metabolic syn‑
drome on subclinical atherosclerosis. Clin Chim Acta. 2007;384:99–104.
 5. Yan E, Chen S, Hong K, Kim WS, Bajpai A, Treyzon L, et al. Insulin, hs‑CRP, 
leptin, and adiponectin. An analysis of their relationship to the metabolic 
syndrome in an obese population with an elevated waist circumference. 
Metab Syndr Relat Disord. 2008;6:64–73. doi:10.1089/met.2007.0027.
 6. Oda E, Kawai R. Comparison between high‑sensitivity C‑reactive protein 
(hs‑CRP) and white blood cell count (WBC) as an inflammatory compo‑
nent of metabolic syndrome in Japanese. Intern Med. 2010;49:117–24.
 7. Esper RJ, Nordaby RA, Vilariño JO, Paragano A, Cacharrón JL, Machado RA. 
Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol. 
2006;235:4.
 8. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: 
testing and clinical relevance. Circulation. 2007;115:1285–95.
 9. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 
2005;111:363–8.
 10. Laaksonen DE, Lakka HM, Salonen JT, Niskanen LK, Rauramaa R, Lakka 
TA. Low levels of leisure‑time physical activity and cardiorespiratory 
fitness predict development of the metabolic syndrome. Diabetes Care. 
2002;25:1612–8.
 11. Huang Y, Liu X. Leisure‑time physical activity and the risk of 
metabolic syndrome: meta‑analysis. Eur J Med Res. 2014;19:22. 
doi:10.1186/2047‑783X‑19‑22.
 12. Kwaśniewska M, Jegier A, Kostka T, Dziankowska‑Zaborszczyk E, 
Rębowska E, Kozińska J, Drygas W. Long‑term effect of different physical 
Page 9 of 10Kwaśniewska et al. Diabetol Metab Syndr  (2015) 7:81 
activity levels on subclinical atherosclerosis in middle‑aged men: a 
25‑year prospective study. PLoS One. 2014;9:e85209. doi:10.1371/journal.
pone.0085209.
 13. Katano S, Nakamura Y, Okuda N, Murakami Y, Chiba N, Yoshita K, Tanaka 
T, Tamaki J, Takebayashi T, Okayama A, Miura K, Okamura T, Ueshima H, 
HIPOP‑OHP Research Group. Relationship between dietary and other 
lifestyle habits and cardiometabolic risk factors in men. Diabetol Metab 
Syndr. 2011;3:30. doi:10.1186/1758‑5996‑3‑30.
 14. Hamdy O, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, et al. Life‑
style modification improves endothelial function in obese subjects with 
the insulin resistance syndrome. Diabetes Care. 2003;26:2119–25.
 15. Mora S, Cook N, Buring JE, Ridker PM, Lee IM. Physical activity and 
reduced risk of cardiovascular events: potential mediating mechanisms. 
Circulation. 2007;116:2110–8.
 16. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake 
DB, et al. National Heart, Lung, and Blood Institute; American College 
of Cardiology Foundation; American Heart Association. Implications of 
recent clinical trials for the National Cholesterol Education Program Adult 
Treatment Panel III guidelines. Circulation. 2004;110(2):227–39.
 17. Fox SM 3rd, Naughton JP, Gorman PA. Physical activity and cardiovascular 
health. 3. The exercise prescription: frequency and type of activity. Mod 
Concepts Cardiovasc Dis. 1972;41(6):25–30.
 18. Kriska AM, Caspersen CJ. Historical leisure activity questionnaire: a collec‑
tion of physical activity questionnaires for health‑related research. Med 
Sci Sports Exerc. 1997;29:S43–9.
 19. Gore C, Booth ML, Bauman A, Owen N. Utility of pwc75% as an estimate 
of aerobic power in epidemiological and population‑based studies. Med 
Sci Sports Exerc. 1999;31:348–51.
 20. Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, et al. 
Assessment of endothelial function by non‑invasive peripheral 
tonometry predicts late cardiovascular adverse events. Eur Heart J. 
2010;31:1142–8.
 21. Gupta AK, Johnson WD. Prediabetes and prehypertension in disease free 
obese adults correlate with an exacerbated systemic proinflammatory 
milieu. J Inflamm. 2010;7:36. doi:10.1186/1476‑9255‑7‑36.
 22. Gupta AK, McGlone M, Greenway FL, Johnson WD. Prehypertension in 
disease‑free adults: a marker for an adverse cardiometabolic risk profile. 
Hypertens Res. 2010;33:905–10. doi:10.1038/hr.2010.91.
 23. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 
2003;111:363–8.
 24. Li J, Flammer AJ, Lennon RJ, Nelson RE, Gulati R, Friedman PA, et al. 
Comparison of the effect of the metabolic syndrome and multiple 
traditional cardiovascular risk factors on vascular function. Mayo Clin Proc. 
2012;87:968–75. doi:10.1016/j.mayocp.2012.07.004.
 25. Gupta AK, Ravussin E, Johannsen DL, Stull AJ, Cefalu WT, Johnson 
WD. Endothelial dysfunction: an early cardiovascular risk marker in 
asymptomatic obese individuals with prediabetes. Br J Med Med Res. 
2012;2:413–23.
 26. Gupta AK, Johnson WD, Johannsen D, Ravussin E. Cardiovascular 
risk escalation with caloric excess: a prospective demonstration of 
the mechanics in healthy adults. Cardiovasc Diabetol. 2013;12:23. 
doi:10.1186/1475‑2840‑12‑23.
 27. Hamburg NM, Larson MG, Vita JA, Vasan RS, Keyes MJ, Widlansky ME, et al. 
Metabolic syndrome, insulin resistance, and brachial artery vasodilator 
function in Framingham Offspring participants without clinical evidence 
of cardiovascular disease. Am J Cardiol. 2008;101:82–8.
 28. Toggweiler S, Schoenenberger A, Urbanek N, Erne P. The prevalence of 
endothelial dysfunction in patients with and without coronary artery 
disease. Clin Cardiol. 2010;33:746–52. doi:10.1002/clc.20836.
 29. Konttinen J, Lindholm H, Sinisalo J, Kuosma E, Halonen J, Hopsu L, 
Uitti J. Association between lowered endothelial function measured 
by peripheral arterial tonometry and cardio‑metabolic risk factors—a 
cross‑sectional study of Finnish municipal workers at risk of diabe‑
tes and cardiovascular disease. BMC Cardiovasc Disord. 2013;13:83. 
doi:10.1186/1471‑2261‑13‑83.
 30. Carnovale V, Paradis ME, Gigleux I, Ramprasath VR, Couture P, Jones PJ, 
et al. Correlates of reactive hyperemic index in men and postmenopausal 
women. Vasc Med. 2013;18:340–6. doi:10.1177/1358863X13507975.
 31. Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. 
Lancet. 2010;375:181–3. doi:10.1016/S0140‑6736(09)61794‑3.
 32. Peterson MD, Al Snih S, Serra‑Rexach JA, Burant C. Android adiposity 
and lack of moderate and vigorous physical activity are associated with 
insulin resistance and diabetes in aging adults. J Gerontol A Biol Sci Med 
Sci. 2015;70(8):1009–17. doi:10.1093/gerona/glv002.
 33. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circula‑
tion. 2002;105(9):1135–43.
 34. Trepels T, Zeiher AM, Fichtlscherer S. The endothelium and inflammation. 
Endothelium. 2006;13:423–9.
 35. Devaraj S, Singh U, Jialal I. Human C‑reactive protein and the 
metabolic syndrome. Curr Opin Lipidol. 2009;20:182–9. doi:10.1097/
MOL.0b013e32832ac03e.
 36. Vu JD, Vu JB, Pio JR, Malik S, Franklin SS, Chen RS, Wong ND. Impact of 
C‑reactive protein on the likelihood of peripheral arterial disease in 
United States adults with the metabolic syndrome, diabetes mellitus, and 
preexisting cardiovascular disease. Am J Cardiol. 2005;96:655–8.
 37. Stibůrková B, Pavlíková M, Sokolová J, Kožich V. Metabolic syndrome, 
alcohol consumption and genetic factors are associated with serum 
uric acid concentration. PLoS One. 2014;9:e97646. doi:10.1371/journal.
pone.0097646.
 38. Lee YJ, Cho S, Kim SR. A possible role of serum uric acid as a marker 
of metabolic syndrome. Intern Med J. 2014;44:1210–6. doi:10.1111/
imj.12588.
 39. Erdogan D, Gullu H, Caliskan M, Yildirim E, Bilgi M, Ulus T, et al. Relation‑
ship of serum uric acid to measures of endothelial function and athero‑
sclerosis in healthy adults. Int J Clin Pract. 2005;59:1276–82.
 40. Grundy SM. Adipose tissue and metabolic syndrome: too much, too little, 
or neither. Eur J Clin Invest. 2015;. doi:10.1111/eci.12519.
 41. Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiol‑
ogy of insulin resistance. Cell Metab. 2012;15(5):635–45. doi:10.1016/j.
cmet.2012.04.001.
 42. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce 
MR, et al. Serum immunoreactive‑leptin concentrations in normal‑weight 
and obese humans. N Engl J Med. 1996;334:292–5.
 43. Leyva F, Godsland IF, Ghatei M, Proudler AJ, Aldis S, Walton C, et al. Hyper‑
leptinemia as a component of a metabolic syndrome of cardiovascular 
risk. Arterioscler Thromb Vasc Biol. 1998;18(6):928–33.
 44. Lopes HF, Klein RL, Garvey WT, Goodfriend T, Egan BM. Influence of 
acute hyperlipidemia to adipocyte‑derived hormones in lean normo‑
tensive and subjects with metabolic syndrome. Diabetol Metab Syndr. 
2014;6(1):132. doi:10.1186/1758‑5996‑6‑132.
 45. Li WC, Hsiao KY, Chen IC, Chang YC, Wang SH, Wu KH. Serum lep‑
tin is associated with cardiometabolic risk and predicts metabolic 
syndrome in Taiwanese adults. Cardiovasc Diabetol. 2011;10:36. 
doi:10.1186/1475‑2840‑10‑36.
 46. Galletti F, Barbato A, Versiero M, Iacone R, Russo O, Barba G, et al. Circulat‑
ing leptin levels predict the development of metabolic syndrome in mid‑
dle‑aged men: an 8‑year follow‑up study. J Hypertens. 2007;25(8):1671–7.
 47. Baden MY, Yamada Y, Obata Y, Hosakawa Y, Saisho K, Tamba S, et al. Serum 
adiponectin level is not only decreased in metabolic syndrome but 
also in borderline metabolic abnormalities. Nutr Diabetes. 2011;1:e18. 
doi:10.1038/nutd.2011.13.
 48. Vega GL, Grundy SM. Metabolic risk susceptibility in men is par‑
tially related to adiponectin/leptin ratio. J Obes. 2013;2013:409679. 
doi:10.1155/2013/409679.
 49. Chen JQ, Huang YY, Gusdon AM, Qu S. Irisin: a new molecular 
marker and target in metabolic disorder. Lipids Health Dis. 2015;14:2. 
doi:10.1186/1476‑511X‑14‑2.
 50. Huh JY, Siopi A, Mougios V, Park KH, Mantzoros CS. Irisin in response to 
exercise in humans with and without metabolic syndrome. J Clin Endo‑
crinol Metab. 2015;100:E453–7. doi:10.1210/jc.2014‑2416.
 51. Hou N, Han F, Sun X. The relationship between circulating irisin levels and 
endothelial function in lean and obese subjects. Clin Endocrinol (Oxf ). 
2014;. doi:10.1111/cen.12658.
 52. Esteve E, Castro A, López‑Bermejo A, Vendrell J, Ricart W, Fernández‑
Real JM. Serum interleukin‑6 correlates with endothelial dysfunction 
in healthy men independently of insulin sensitivity. Diabetes Care. 
2007;30:939–45.
 53. Vita JA, Keaney JF Jr, Larson MG, Keyes MJ, Massaro JM, Lipinska I, et al. 
Brachial artery vasodilator function and systemic inflammation in the 
Framingham Offspring Study. Circulation. 2004;110:3604–9.
Page 10 of 10Kwaśniewska et al. Diabetol Metab Syndr  (2015) 7:81 
 54. Weiner SD, Ahmed HN, Jin Z, Cushman M, Herrington DM, Nelson 
JC, et al. Systemic inflammation and brachial artery endothelial 
function in the Multi‑Ethnic Study of Atherosclerosis (MESA). Heart. 
2014;100:862–6.
 55. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte 
emigration: the multistep paradigm. Cell. 1994;76:301–14.
 56. Hartman J, Frishman WH. Inflammation and atherosclerosis: a review 
of the role of interleukin‑6 in the development of atherosclerosis and 
the potential for targeted drug therapy. Cardiol Rev. 2014;22:147–51. 
doi:10.1097/CRD.0000000000000021.
 57. Hallmark R, Patrie JT, Liu Z, Gaesser GA, Barrett EJ, Weltman A. The effect 
of exercise intensity on endothelial function in physically inactive lean 
and obese adults. PLoS One. 2014;9(1):e85450. doi:10.1371/journal.
pone.0085450.
 58. Kirma C, Akcakoyun M, Esen AM, Barutcu I, Karakaya O, Saglam M, et al. 
Relationship between endothelial function and coronary risk factors in 
patients with stable coronary artery disease. Circ J. 2007;71(5):698–702.
 59. Sauder KA, West SG, McCrea CE, Campbell JM, Jenkins AL, Jenkins 
DJ, Kendall CW. Test‑retest reliability of peripheral arterial tonom‑
etry in the metabolic syndrome. Diab Vasc Dis Res. 2014;11:201–7. 
doi:10.1177/1479164114525971.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
